All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

Final Appraisal Recommendation
Advice No: 1316 – May 2016

Pasireotide (as pamoate) (Signifor®) 20 mg, 40 mg, 60 mg powder and solvent for suspension for injection

Submission by Novartis Pharmaceuticals UK Ltd

Recommendation of AWMSG

Pasireotide (as pamoate) (Signifor®) is recommended as an option for use within NHS Wales for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.

Additional note(s):

- AWMSG considered that pasireotide (as pamoate) (Signifor®) satisfies the AWMSG criteria for ultra orphan drug status.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 643), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Novartis Pharmaceuticals UK Ltd
Date of first issue	May 2016
Last reviewed	June 2019